Allergic Rhinitis Drugs Market Forecast 2016-2026

31 August 2016
Pharma

A new report by visiongain predicts that the Allergic Rhinitis Drugs market will reach $16,500m in 2026. This forecast and others appear in - Allergic Rhinitis Drugs Market Forecast 2016-2026: Analysis of the Current Trend and Pipeline Opportunities in the Intranasal Antihistamines, Intranasal Corticosteroids, Oral Antihistamines, and Immunotherapy and Vaccines Markets, Including Current Products such as Patanase, Dymista, Nasonex, Allegra, and Staloral with Assessment of Key Companies in the Allergic Rhinitis Market Including GSK and Merck & Co. published in September 2016. Visiongain is a business information provider based in London, UK.
The Allergic Rhinitis Drugs Market Forecast 2016-2026: Analysis of the Current Trend and Pipeline Opportunities in the Intranasal Antihistamines, Intranasal Corticosteroids, Oral Antihistamines, and Immunotherapy and Vaccines Markets, Including Current Products such as Patanase, Dymista, Nasonex, Allegra, and Staloral with Assessment of Key Companies in the Allergic Rhinitis Market Including GSK and Merck & Co., report examines the current and future trends in the Allergic Rhinitis Drugs Market with particular focus on recent pivotal developments in the sector involving patent expires, OTC swithces, launch of new drugs and pipeline products. These developments in addition to changes in population demographics are changing the landscape of the allergic rhinitis drugs market.

Allergic Rhinitis Drugs are used to treat and manage allergic rhinitis symptoms. This is irritation and inflammation of the lining of the nasal passages which is caused by an allergic reaction. The symptoms are sneezing, nasal congestions, itching and rhinorrhoea. Allergic Rhinitis is very common, leading to a large patient population.

The driving force behind growth in this market is the increasing prevalence of allergic rhinitis, new products launching onto the market and OTC switches. There is an increased demand for treatment of allergic rhinitis, as a result of climate change and industrialisation. The allergic rhinitis drugs market is increasingly expected to innovate in order to meet these demands in a safe manner, focusing intention on treatment rather than symptomatic relief.

In this report, we examine in detail the factors which are driving the Allergic Rhinitis Drugs Market growth, the key companies currently operating in the allergic rhinitis drugs market including their product pipelines. We also examine key national markets and discuss trends and variations within these markets, alongside an analysis of allergic rhinitis drugs.

The Allergic Rhinitis market segments examined in this report are: Intranasal Corticosteroids, Oral Antihistamines, Immunotherapy and Vaccines, Intranasal Antihistamines. National Markets focused on are the US, China, Japan, EU5 (Germany, UK, Italy, France and Spain), Brazil, Russia and India.

Using both primary and secondary research, forecasts have been built for the major submarkets, leading products and leading national and regional markets, accompanied by text giving a thorough explanation of events thought to shape the market currently and in the future.

Visiongain’s report also provides an analysis of the current leading players in the Allergic Rhinitis Drugs Market. Historical financial performance is analysed, along with a breakdown of each company’s leading products and pipeline research, and recent merger & acquisition information, with an analysis of news that may influence the course of the company.

Allergic Rhinitis Drugs Market Forecast 2016-2026: Analysis of the Current Trend and Pipeline Opportunities in the Intranasal Antihistamines, Intranasal Corticosteroids, Oral Antihistamines, and Immunotherapy and Vaccines Markets, Including Current Products such as Patanase, Dymista, Nasonex, Allegra, and Staloral with Assessment of Key Companies in the Allergic Rhinitis Market Including GSK and Merck & Co. adds to visiongain’s range of analytical reports on industries and markets in healthcare.

For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.

Recent News

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

“Global Ophthalmic Equipment market set to grow to $75bn by 2024” says new Visiongain report

here is a growing demand for ophthalmic equipment such as vision care products and ophthalmology surgical devices, mainly due to the increasing incidence of myopia across the world.

03 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever